The study focuses on the efficacy of citrate-stabilised gold nano-particles (AuNPs) in conjugation with T-cell immunoglobulin and mucin domain 3 as a medium for drug delivery for leukemia treatment. The targeted drug delivery model will specifically target the faulty malignant cells of leukemia via side-passing the normal proliferating haematopoietic stem cells and thereby helping to reduce the limit of cyto-toxicity. The study also uncovered the opportunities in the domain of cancer nanomedicine that capitalize the increasing understanding of the tumour biology, the cell-surface receptors of the cancer molecules and their interactions with the nano-paticles and thereby helping to develop effective nano-therapeutic approaches for cancer patients.